America’s AI Action Plan & Implications for AI-Powered Clinical Support Tools
As federal AI policy takes shape, it’s clear that healthcare innovation is entering a new era — one that demands both technical progress and public trust. The White House’s latest AI Action Plan pushes for national standards, clinical validation, and regulatory sandboxes to accelerate the safe, responsible use of AI in healthcare. It also warns that tools deployed without transparency, oversight, or clinical grounding may face new scrutiny — especially as states begin passing their own health AI laws. What is in the policy changes? The White House recently unveiled its “AI Action Plan,” which includes plans to tie federal AI funding access to a state’s regulatory position, potentially negatively impacting states that impose what the administration deems “burdensome” AI regulations. Another thrust of the plan is to establish regulatory sandboxes (AI Centers of Excellence), backed by NIST*-led health AI standards. These initiatives are framed around speeding up AI innovation—especially in healthcare and drug discovery. * National Institute of Standards and Technology Why does this matter for AI-powered Clinical Support Tools (CST) in Oncology? What should providers of AI-powered medical tools do? AI in healthcare is not just a tech problem — it’s a policy, workflow, and trust challenge. This legislation underscores how critical it is to be proactive at the intersection of innovation, transparency, and ethical design. I would love to hear from other founders or clinicians navigating this space—how are you approaching regulation and federal‑state interplay? Anna Forsythe is the Founder and President of Oncoscope-AI, the first platform to bring together real-time oncology treatment data, clinical guidelines, research publications, and regulatory approvals — all in one place, just like Expedia for cancer care. Available free to oncology professionals worldwide, Oncoscope-AI is redefining how cancer care information is accessed and applied. A clinically trained Doctor of Pharmacy (PharmD), Anna also holds a Master’s in Health Economics and Policy from the University of Birmingham (UK) and an MBA from Columbia University. She previously co-founded Purple Squirrel Economics (acquired by Cytel in 2020) and led Global Value and Access at Eisai Pharmaceuticals, following earlier roles at Novartis and Bayer in clinical research and health economics.